June 28, 2022
Kyowa Kirin said on June 27 that the company gained the blessing of a key European panel for the label expansion of its anti-FGF23 monoclonal IgG1 antibody Crysvita (burosumab) for the treatment of tumor-induced osteomalacia (TIO). The drug received a...read more